Nature Communications (May 2020)
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- So Ra Kim,
- Sang-Guk Lee,
- Soo Hyun Kim,
- Jin Hee Kim,
- Eunhye Choi,
- Wonhee Cho,
- John Hoon Rim,
- Inhwa Hwang,
- Chan Joo Lee,
- Minyoung Lee,
- Chang-Myung Oh,
- Justin Y. Jeon,
- Heon Yung Gee,
- Jeong-Ho Kim,
- Byung-Wan Lee,
- Eun Seok Kang,
- Bong-Soo Cha,
- Myung-Shik Lee,
- Je-Wook Yu,
- Jin Won Cho,
- Jung-Sun Kim,
- Yong-ho Lee
Affiliations
- So Ra Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Sang-Guk Lee
- Department of Laboratory Medicine, Yonsei University College of Medicine
- Soo Hyun Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Jin Hee Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Eunhye Choi
- Department of Laboratory Medicine, Yonsei University College of Medicine
- Wonhee Cho
- Exercise Medicine Center for Diabetes and Cancer Patients, ICONS, Yonsei University
- John Hoon Rim
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Inhwa Hwang
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Chan Joo Lee
- Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine
- Minyoung Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Chang-Myung Oh
- Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology
- Justin Y. Jeon
- Exercise Medicine Center for Diabetes and Cancer Patients, ICONS, Yonsei University
- Heon Yung Gee
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Jeong-Ho Kim
- Department of Laboratory Medicine, Yonsei University College of Medicine
- Byung-Wan Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Eun Seok Kang
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Bong-Soo Cha
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Myung-Shik Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- Je-Wook Yu
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
- Jin Won Cho
- Department of Systems Biology, Glycosylation Network Research Center, Yonsei University
- Jung-Sun Kim
- Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine
- Yong-ho Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-15983-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
SGLT2 inhibitors, a class of type 2 diabetes medication, reduce cardiovascular events in patients beyond expectation from blood sugar control. Here the authors report a randomized controlled trial showing that SGLT2 inhibitors reduce inflammasome activation in peripheral macrophages, which may contribute to the cardiovascular protection.
